awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0
Q36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Prote
P2860
Q36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36073609-1EAB9019-0083-4D53-8ABA-8E03AE5010A0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bd0c273c428f276f9f488db87285868f75023919
P2860
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res